Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. 1 There have been only modest changes in the treatment of AML over the past 40 years and the prognosis remains poor ...

SAN CARLOS, Calif., Nov. 19, 2025 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the ...

SAN FRANCISCO, CA--(Marketwired - Jun 1, 2015) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced positive data from several preclinical studies characterizing the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing ...

NEW YORK--(BUSINESS WIRE)--iCell Gene Therapeutics, LLC announced results from a study ongoing at Chengdu Military General Hospital of ICG144, the first CLL1-CD33 Compound CAR T-cell (cCAR) in ...

M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...

As neuroinflammation becomes ever more deeply implicated in Alzheimer’s disease, therapies targeting this process are starting to enter clinical trials. At the 14th International Conference on ...

Antibody-based therapeutics are valuable tools for the treatment of many human diseases. For example, antibody-based immunotherapies targeting the leukemia antigens CD19 and CD20 have been remarkably ...

SAN FRANCISCO, CA--(Marketwired - Aug 10, 2016) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an ...